reason report
bottom line lower pt ci
tepid quarter view transform pbm
competit landscap regulatori chang pose challeng
amid integr esrx asset see impact
chang commerci competit landscap particularli impact
given player grow market share self
insur stop loss segment challeng
uhc emerg even pose
threat view ci domin select market
employe base total cost care valu proposit unfett
legaci rebat driven model pbm commerci
rebat pass bottom line plan
pbm landscap gotten fierc competit insourc
wcg even ci amid larg vertic consolid
alreadi creat three larg player share drive fierc
competit ci select market growth slow
compar histori pbm margin look weaker support
anecdot commentari price competit esrx larg
player ci report post modest beat rais
enough allevi concern retent outlook
lower histori offer window margin
profil post sell season chang disposit rebat
 busi model pbm commerci part would
expect bigger rais unclear synergi
acceler beyond mm margin pressur
elsewher offset upsid report
less price aggress also transpar disclos synergi
mm seem right zone new pt contempl
multipl averag ep
beat rais lower anticip ci post modest beat
ep rais guidanc line consensu
revenu miss modestli though guidanc rais
stronger membership pharmaci revenu consolid
solid beat somewhat obscur
higher expect tax group disabl saw yoy
margin compress though integr medic segment enjoy
membership top line growth along modestli expand margin
average
net debt total capit
price-to-earnings lt ep growth
share outstand mil share outstand
estimate lt ep growth compound-annual-growth-rate
year price history/av daili volume mil ci
compani inform svb leerink llc research
revenu ep forma ci-esrx ex-antm
revenu billion ep exclud item non-gaap ep
pleas refer page import disclosur price chart analyst certif
ci domin select market challeng new
entrant view emerg even
pose threat ci domin select market employe
base new entrant unfett rebat spread price
issu plagu legaci pbm allow effici
realiz total cost care valu proposit ci select
market growth slow seem earli
inning push segment market
hipf moratorium may caus broader slowdown self
insur stop loss unclear time slowdown
growth self insur stop loss broader slowdown given
hipf tax holiday fulli insur employ may choos opt self
insur stop loss lower premium environ absent tax
could drive membership growth acceler ci hipf
may return could catalyz greater adopt
esrx synergi integr may offer better price discount
commerci broker survey indic discount drive
health pbm landscap becom fierc competit
emerg new vertic integr unh/
optumrx aet/caremark ci/esrx antm/ingeniorx
pbm landscap becom increasingli competit insourc
wcg even ci amid larg vertic consolid creat
three larg player share drive fierc competit
pbm margin look weaker support anecdot commentari price
competit esrx larg player
uncertainti legaci pbm busi model increas
competit weigh margin retent outlook
lower histori offer window margin profil
post sell season chang disposit rebat
busi model pbm commerci part
expect bigger beat rais unclear synergi
acceler beyond mm margin pressur
elsewher offset upsid report
less price aggress also transpar disclos synergi
mm seem right zone
maintain estim lower pt reflect increas
uncertainti pt contempl multipl averag
ep
lower pt ci tepid quarter view
transform pbm competit landscap regulatori chang pose
challeng amid integr esrx asset
see impact chang commerci competit landscap particularli
impact given player grow market share self-insur
stop loss segment challeng uhc
emerg even pose threat view ci domin
select market employe base total cost care valu proposit
unfett legaci rebat driven model pbm commerci
rebat pass bottom line
plan pbm landscap gotten fierc competit insourc
wcg even ci amid larg vertic consolid alreadi creat three larg
player share drive fierc competit ci select market
growth slow compar histori pbm margin look weaker support
anecdot commentari price competit esrx larg player
ci report post modest beat rais enough allevi
concern retent outlook lower histori offer
window margin profil post sell season chang disposit
rebat busi model pbm commerci part
would expect bigger rais unclear synergi
acceler beyond mm margin pressur elsewher offset
upsid report less price aggress also
transpar disclos synergi mm seem right zone pt
contempl multipl averag ep
rais lower anticip
ci post modest beat ep rais guidanc line
consensu revenu miss modestli though guidanc rais
stronger membership pharmaci revenu consolid solid
beat somewhat obscur higher expect tax group
disabl saw yoy margin compress though integr medic
segment enjoy membership top line growth along modestli expand margin
tepid modest rais
consolid bp tax rate came higher expect
ci earningsreport estimatesstreetaccount consensusreport sequentialreport yoytot net pre tax incom loss group disabl incom loss oper per disabl n/acorpor ci metricsreport estimatesstreetaccount consensusreport sequentialreport yoykey metricsconsolid bpsglobal healthcar oper expens bpsday claim corpor
ci membershipreport estimatesstreetaccount consensusreport sequentialreport yoyhealth enrollmentcommerci custom integr health care medic medic membershipmedicar part corpor
ci qsum segment adj incom oper pre-tax
dcp day similar
report sequentialreport yoyintegratedadj incom oper pre margin pre servicesadj incom oper pre margin pre incom oper pre margin pre disabl operationsadj incom oper pre margin pre claim payabl corpor
ci rais ep guidanc revenu
guidanc would expect bigger rais
unclear synergi acceler beyond mm margin
pressur elsewher offset upsid
ci rais revenu ep guidanc
ep guidanc re-affirmed though oper challeng remain
view ci long road ahead fundament transform realign pbm
landscap transit in-hous pbm ingeniorx simultan transfer
ci optum rx pbm esrx heavi lift renew sell season juli
remain key catalyst must contempl drug cost save enjoy
employe commerci stronghold transit optumrx
continu present competit threat
ci guidanceguid leerink estimatesconsensu estimatesconsolid revenueadjust expens incom incom oper pre-tax integr incom oper pre-tax supplement benefit mm adjust pharmaci claim adj net incom mm tax guidanc exclud share corpor
though ci re-affirmed ep management must clearli show achiev
growth amid transform competit regulatori landscap
manag confid hit
view emerg even pose threat ci domin
select market employe base new entrant unfett rebat spread
price issu plagu legaci pbm allow effici realiz total
track achiev ep target first quarter result demonstr strong perform momentum give us confid achiev increas outlook revenu earn ep remain track achiev ep target per share look forward go deeper well long-term growth strategi investor day later month david cordani ceo earn call cigna corpor
cost care valu proposit ci select market growth slow
seem earli inning push segment market
select middl market membership growth slow
antm commerci busi start see share gain improv local market
execut coordin center excel leverag effici drive
systemat underwrit sale process expect continu share gain
commerci segment ingeniorx implement commenc may
antm invest heavili commerci segment
quietli becom forc commerci market partner innov start-up
take bigger commerci focus peer fact cite leader within
employ benefit survey conduct dec
return growth small group employ segment seek
penetr market innov partnership tech-en start-up
accolad link dr demand link lower presenc commerci segment
make possibl move innov approach larger commerci
becom forc commerci market innov partnership dr
demand accolad
 nfp bcb led rate price
follow highmark
ci led rate benefit design
follow nfp bcb
note rank scale best worst
note rank scale best worst
unclear time slowdown growth self insur stop loss
broader slowdown given hipf tax holiday fulli insur employ may choos opt
self-insur stop loss lower premium environ absent tax
could drive membership growth acceler ci hipf may return
could catalyz greater adopt esrx synergi integr may offer
cvh hipantmunhhighmarknfp bcbshumbrok rate carrier best cvh unhnfp bcbscihumbrok rate carrier benefit best corpor
discount bundl product would drive switch
medacorp survey health insur broker price novemb rank scale best worst
emerg new vertic integr unh/optumrx aet/caremark
ci/esrx antm/ingeniorx pbm landscap becom increasingli competit
start believ new parlay portion medic cost advantag
toward medic underwrit market share across medicar advantag commerci market
compress margin
insourc wcg even ci amid larg vertic consolid creat three larg
player share drive fierc competit pbm margin look weaker support anecdot
commentari price competit esrx larg player
compani report svb leerink estim analysi drug channel institut nhe
recent healthcar servic roundtabl event audienc primarili
compris institut public equiti investor expect vertic consolid across
pbm mco drive competit price
attende healthcar servic roundtabl event expect consolid drive competit
regulatori uncertainti legaci pbm busi model increas competit weigh
margin retent outlook lower histori offer window
margin profil post sell season chang disposit rebat
busi model pbm commerci part
expect ci well prepar deal rebat elimin part less certain
impact elimin commerci rebat spread price margin
manag tight-lip impact regulatori chang may one thing
abundantli clear ebitda margin continu declin expect trend
abat near term
potenti regulatori chang pbm price model drug cost make pbm margin uncertain
hh part rule mid-april sec deliv speech nation busi group
detail import propos part rule though signific
pushback major stakehold hh part rule expect propos
implement execut author believ headlin
implement risk associ rule cigna express script second
regulatori environ creat uncertainti pbm marginsso whether spread price chang postur rebat otherwis movement subcompon portfolio total cost total valu proposit need work proven abil innov make sure abl get fair sustain sharehold return margin excit abil lead chang marketplac oppos resist david michael cordanipresid chief execut offic director corp big pictur discuss past look call deflationari environ broadli rel pharmaci express script earli identifi continu make sure evolv product program servic client well manufactur recognit david michael cordanipresid chief execut offic director corp corpor
hh part rule would incur chang rebat commerci market howev
speech nation busi group april secretari emphas
import ultim reform commerci market well hope chang
gov sector spur addit reform commerci player
possibl congress propos legisl commerci market well view
believ current bake sentiment
headlin number one propos rebat rule meaning impact growth earn trajectori specif note propos rule evalu next day appli medicar advantag pdp mechan exist term way rate built medicar advantag well pdp larg design flow respect rebat pass-through way rate built see major implic busi portfolio david michael cordanipresid chief execut offic director corp corpor
sec azar want chang commerci market time
nation busi group
nonetheless pbm said finan impact minim issu white paper
disclos expect pass rebat link suggest
elimin rebat would manag rebat fact pass
pbm employ subsid employe health insur premium ci op /esrx
disclos rebat mm mp state rebat mm
sec express need also elimin rebat commerci marketbut want encourag shift commerci space manag benefit employ togeth cover prescript drug mani american part mani know nbgh conduct survey larg employ last year show clear desir chang rebat system alex iith nation busi group april plan part would technic extend commerci market clear propos rulemak enforc rule take account possibl negoti bleed part market commerci market alex iith nation busi group april corpor
ci file disclos mm retain rebat spend esrx inclus commerci
although believ mani politician statement regard drug price suppli chain
reform simpli rhetor remain possibl materi legisl propos
would alter landscap senat financ committe april much talk
legisl could pass focu remain part rule
howev lawmak becom increasingli skeptic pbm role keep drug
cost
takeaway pbm senat hear
pbm provid valu keep drug affordableoutsid negoti pharma extend po rebat improv medic adher provid real-tim price physician dispens gener productspbm give patient choic product prevent drug would co-pay value-bas care arrang lower cost care condition-specif approach manag chronic condit effectivelyguarante net price modelreaffirm rebat pass throughin medicar pass disclos medicar rebat pass overal approxim pass rebat fee client plan discount pass directli plan sponsorspbm exec larg oppos hh rule premium would increas rebat use plan keep cap premium increasesreb drug total part spendth propos requir pharma compani lower priceonli small amount beneficari benefitexec support transparency support medpac support public transpar would make pbm like negoti effect pharma manufactur client audit right look rebat contract transpar custom provid patient transpar negoti manufactur brand rebat around noth lower cost requir pharma drug lower drug exec favor government negoti priceclin expertis negoti manufactur govern negoti overal govern must formulari expertis effect support government negoti price patent issu biosimiliar biosimilar govern negoti would higher list price go govern negoti competit solut target pharma manufacturersmak gener marketplac incentiv manufactur make absolut support competit marketplac reduc member oop burden use biosimilar much lower countri patent issu biosimiliar lot done increas competit biosimilar eu less market america fda provid solut corpor
representativedericaricepresid caremarkstev miller mdchiefclin officerjohn princeceo optumrxwilliam flemingpresid healthcar servicesmik kolar jdinterim presid mm mmmarket drug pass payorspo mm commerci member one pdp option offer mm commerci member commerci health plan clientselimin spread price yespossiblyno positionyesyescost save save client saw drug price declin member spent onrx save employerdrug trend lowestin mm save base value-bas arrangementsintegr pharmaci medic reduc annual medic cost pmpm medic cost savingssav member averagecommun mental health center reduc cost oop posreb save rate clinic reduct readmiss onemedprogrammaximizeyourbenefiprogram save member mm increment valu creat drug trend neg trend lower drug pricesmor flexibl negoti medicar medicaidincreas price data transparencyimprov pharma competit increas access gener biosimilarschang part benefit designso senior incur less oop cost increas pharma competitionincreas access gener biosimilarsincreas price data transparencyincreas value-bas contractsen util manag increas negoti medicareincreas pharma competitionincreas access gener biosimilarsallow medicar medicaid use real-tim benefit toolsen util manag increas negoti medicarechang part benefit designso senior incur less oop cost increas pharma competitionincreas access gener biosimilarsmodern part programincreas transpar adopt real-tim benefit tool allow greater access cmss dir data electron prescribingincreas pharma competitionincreas access gener cigna corpor
unclear synergi acceler beyond mm margin pressur
elsewher offset upsid report less price aggress
also transpar disclos synergi mm seem right zone
unclear cigna abl acceler synergi
administr effici medic save drive share gain region plan admin total cost savingsmed pmpi mcopbmsourc compani report svb leerink estim note pmpi per member per cigna corpor
target price multipl base averag ep
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
pt contempl price-to-earnings averag ep
risk invest thesi valuat
legisl regulatori polici chang could either dis-intermedi
insur us benefit marketplac place unforeseen top-lin margin
headwind commerci medicar advantag medicaid dual elig book
not-for-profit health insur price irrat commerci health benefit
acceler employ exit sponsorship health benefit us
marketplac post implement afford act
advers select public exchang protect adequ given delay
true-up govern payment
acquisit asset without attract return capit investor
organiz and/or oper risk drive execut mis-step downsid risk
earn
primari valuat methodolog base absolut price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
price target base price-to-earnings averag ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti econom downturn
provid re-up intens servic deliveri cobra acceler uptak
member util care advanc layoff pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz econom downturn
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus
longer term state-bas insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress potenti downsid membership
polit shock lead singl payer
compani specif risk signific declin equiti market could result increas fund
compani pension oblig polit legal oper regulatori econom
risk foreign oper
integr regulatori risk across merg ci esrx
pt contempl price-to-earnings averag ep
risk valuat includ
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid entitl program
state feder suprem court level also risk consid
pt contempl price-to-earnings consensu price-to-earnings
ep
underwrit risk aet asset trade peak margin commerci fulli
insur though medacorp commerci broker price survey give us confid
price environ remain appropri hard offer flat even potenti
modestli expand underwrit margin risk potenti futur margin compress
aet health insur even meaning given associ neg impact
debt ebitda load compani need focus debt
pay next month departur shawn guertin aet cfo
slate becom cfo make us less confid price postur
health insur book commenc new bulk compet
share gain commerci medicar advantag market
macroeconom risk risk macroeconom downturn higher
defens pbm sub sector given cyclic correl retail front store
sale employ data
regulatori risk convinc pbm add valu earn
low probabl threat potenti drug manufactur rebat elimin off-set
new busi model includ administr fee and/or perform guarante
expos pbm retail pharmaci busi compar
player pbm risk
execut integr risk face greater risk well given integr
pbm broader organ also transform agenda around
build retail front model amid risk leverag balanc sheet
e-commerce/amzn greater exposur eros sale on-line
channel well given exposur retail front store retail pharmaci e-
commerc though larg price retail multipl expect less like
pursu agenda becom pbm given associ integr clinic evid
base treatment guidelin integr provid network domin captiv pbm
model mega deal
remain posit reiter op rate month pt
contempl price-to-earnings averag ep
risk invest thesi valuat legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn acceler medic cost trend
util improv economi servic arena yet yield adequ
return capit
sotp valuat point per share expect premium toward much
potenti takeout price per share see like buyer light
synergi medicaid complet pbm across ingeniorx optum rx
optum rx seek specialti rx expect look region player shore
medicaid pois well build third-parti servic platform best
place well pay cash also like interest given medicaid focu strategi
bring pbm in-hous would like pay asset equiti rather cash
delev fide transact financi buyer also like suitabl strateg
buyer identifi
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid
scale issu result loss specialti rx pharmaci contract
acquisit offer adequ return capit
upsid takeout substanti premium key risk
carve-out behavior health servic current state contract
pt contempl multipl averag
ep may day dive top-lin growth continu margin expans
 strategi may import posit catalyst
risk highlight first spike util on-board new state contract
dual elig integr second state-bas insur exchang result advers
select reduc sustain earn power third state-bas contract rate increas
suffici cover medic trend off-set industri fee medicaid premium fourth risk re-
procur exist contract could creat substanti downsid risk volatil fifth
legisl judici risk manag medicaid entitl extrem case singl
payer model also possibl downsid
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
rate outperform price target contempl price-to-earnings
averag cash ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti double-dip recess
provid re-up intens servic deliveri cobra acceler uptak member util
care advanc lay-off pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz double-dip recess
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus substanti
long-term state base health insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress also potenti downsid membership
risk relat collect industri fee medicar medicaid premium
polit shock lead singl payer
compani specif risk downsid risk price target includ acquisit asset
arena yield adequ return capit
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free yield ratio also inform potenti multipl expans
except low ratio and/or high free yield point potenti greater
base rate wcg outperform pt contempl price-to-earnings
averag ep
downsid risk price target includ execut new state contract dual elig
award rate increas suffici cover medic trend state clawback tax off-set tax
reform tailwind potenti dial medicaid expans ky upsid risk price
target includ take-out larger player
cigna inc ci incom mail order pharmaci invest invest gain revenu expenseshealth care medic claim benefit mail order pharmaci cost good acquisit oper expens exclud special deal synergi benefit continu oper incom tax net growth yoyrevenu growth metricstot adj gdr gener dispens ep corpor
health enrol access/oth guarante guarante legaci servic great west medic membership medic membership gw corpor
